Back to search

Takeda UK Ltd

26 contracts won£8,607,955,899 total value

Every public sector contract Takeda UK Ltd has won, with the buyer, value and end date for each. When these contracts approach their end date they usually return to the market. Business predicts when, follows Takeda UK Ltd for you, and alerts you the moment a renewal goes live.

Where they win

The sectors, tender types and buyers where Takeda UK Ltd wins most often.

See every live NHS tenders and find your next contract before they do.

See all NHS buyers and UK contract awards.

Sectors

Healthcare & Medical26

Top Buyers

NHS England
18 contracts
£8,113,655,311
The Common Services Agency (more commonly known as NHS National Services Scotland) (NSS)
2 contracts
£12,087,463
The NHS Commissioning Board (operating under the name of NHS England)
2 contracts
The Common Services Agency (more commonly known as Public Services Delivery Scotland) (PSD Scotland)
1 contract
£47,898,609
The Common Services Agency (more commonly known as NHS National Services Scotland) ("NSS")
1 contract
£6,079,596
Regional Business Services Organisation, Procurement and Logistics Service
1 contract
£7,936
Atamis LTD
1 contract
£428,226,984

Awards(26)

Sort:

NP90726m Vedolizumab (Entyvio®)

The Common Services Agency (more commonly known as Public Services Delivery Scotland) (PSD Scotland)
Scotland
£47,898,609
Awarded 24 Jun 2026

Generic, Branded Generic & Proprietary Medicinal Products - Group 18

Regional Business Services Organisation, Procurement and Logistics Service
Belfast
£7,936
Awarded 23 Jun 2026

Leuprorelin (Prostap®)

The Common Services Agency (more commonly known as NHS National Services Scotland) (NSS)
Scotland
£2,625,907
Awarded 5 Nov 2025

NHS Branded Medicines Tranche B - MAE & NOFE - 1 September 2025

NHS England
Runcorn
£986,282,758
Awarded 1 Jul 2025
Ends 31 Aug 2027

NP48925d Hereditary Angioedema Branded Medicines (Cinryze and Takhzyro)

The Common Services Agency (more commonly known as NHS National Services Scotland) (NSS)
Edinburgh
£9,461,556
Awarded 4 Apr 2025

NHS Framework Agreement for Branded Medicines - Proprietary Category Tender

NHS England
Runcorn
£1,241,520,444
Awarded 24 Mar 2025
Ends 30 Apr 2029

NHS Framework Agreement for Human Albumin & Normal and Anti-D Immunoglobulin

NHS England
Scotland
£905,187,090
Awarded 19 Dec 2024
Ends 31 Dec 2027

NHS Branded Medicines Tranche Framework for London and South of England

NHS England
Runcorn
£380,950,720
Awarded 22 Jul 2024
Ends 31 Aug 2026

Enzyme Replacement Therapy Medicines

The Common Services Agency (more commonly known as NHS National Services Scotland) ("NSS")
Edinburgh
£6,079,596
Awarded 19 Jul 2024

NHS Framework - Blood Disorders including Haemophilia A and B - July 2024

NHS England
Runcorn
£765,000,000
Awarded 31 May 2024
Ends 30 Apr 2027

NHS Framework Agreement for Branded Medicines - National Tender - 1 May 2024

NHS England
Runcorn
£1,009,500,000
Awarded 5 Apr 2024
Ends 30 Apr 2028

NHS National Generic Pharmaceuticals Wave 14c (CF Award - Part 2)

NHS England
Runcorn
Not specified
Awarded 4 Mar 2024
Ends 31 May 2027

NHS South of England Branded Medicines - Tranche A - September 2023

NHS England
Runcorn
£249,832,000
Awarded 18 Jul 2023
Ends 31 Aug 2025

NHS London Branded Medicines - Tranche B - September 2023

NHS England
Runcorn
£231,083,000
Awarded 14 Jul 2023
Ends 31 Aug 2025

NHS National Generic Pharmaceuticals Wave 14b

Atamis LTD
Runcorn
£428,226,984
Awarded 7 Jul 2023
Ends 30 Sept 2025

NHS Framework Agreement-Branded Medicines - National Proprietary Pharmaceuticals

NHS England
Runcorn
£304,504,000
Awarded 24 Apr 2023
Ends 30 Apr 2025

NHS Midland & East Branded Medicines, Tranche B & Annual Tranche

NHS England
Runcorn
£480,429,000
Awarded 13 Feb 2023
Ends 28 Feb 2025

NHS Framework for North of England Branded Medicines Tranche A & Annual Tranche

NHS England
RUNCORN
£261,970,000
Awarded 8 Feb 2023
Ends 28 Feb 2025

NHS National Generic Pharmaceuticals Wave 14a

NHS England
East Midlands
£207,982,407
Awarded 14 Dec 2022
Ends 31 Jan 2025

Hereditary Angioedema

NHS England
Scotland
£74,500,000
Awarded 20 Jun 2022
Ends 31 Dec 2023

Know when Takeda UK Ltd's contracts come up for renewal

Business predicts when each of these contracts is due to be re-tendered, follows Takeda UK Ltd for you, and alerts you the moment a renewal goes live, so you can bid before the incumbent locks it in again.

Page 1 of 2

Why track Takeda UK Ltd?

Takeda UK Ltd is an active supplier to UK public sector buyers. Their contract history is one of the clearest guides to where the work is: which authorities they serve, what those contracts are worth, and, most usefully, when each contract is due to end. A contract nearing its end date is an opportunity, because the buyer will usually run the work again.

How renewal tracking works

We aggregate Takeda UK Ltd's award notices from 600+ UK and Irish sources and read the end date on each contract. From those dates, Business predicts when each contract is likely to be re-tendered and, if you follow the supplier, alerts you the moment a matching tender goes live. That head start lets you speak to the buyer and prepare a bid before the incumbent is confirmed again.

What you can do here

  • Review the full history. Every contract Takeda UK Ltd has won, with the buyer, value and dates for each.
  • Spot upcoming renewals. Contracts approaching their end date are the ones most likely to reopen.
  • Track and get alerted. Follow Takeda UK Ltd and be notified when their contracts come up again (Business).
  • Benchmark and target. See which buyers rely on them and at what value, then focus where you can win.

Frequently asked questions

Where does this data come from?

Official UK and Irish contract award notices, aggregated from 600+ sources and updated daily.

Is the contract history free?

Yes. The full award history, values and buyers are free to browse. Predicted renewal dates, following a supplier and renewal alerts are part of our Business plans.

How do you predict renewals?

From the end dates and durations recorded on awarded contracts. A contract at or near its end date is a strong candidate to return to the market.